Gylden is a clinical-stage, privately held biotechnology company, headquartered in Abingdon, Oxfordshire, UK, with R&D and GMP manufacturing facilities in Milton Park, Oxfordshire, UK, an operating subsidiary in Doylestown, Pennsylvania, USA and a manufacturing facility in Fremont, CA, USA. The Company is pioneering the development of synthetic T cell-priming vaccines/immunotherapies designed to mimic the body’s natural cellular immune response to destroy and clear pathogen-infected cells to protect against some of the world’s most urgent health threats. The candidates are designed for delivery via novel skin immunisation into the epidermal layer, aiming to ease the burden and logistics of traditional preventative methods. 

Gylden’s first indications pursued are against infectious diseases: [i] including core candidates for Betacoronaviruses, Dengue Fever and Universal Influenza (including Pandemic Influenza), as well as [ii] intra-cellular bacterial infectious disease. Additional products include a patch-based therapeutic drug for migraine, and candidates for cardiometabolic disorders, as well as cancer immunotherapy. Gylden's product pipeline includes innovative candidates with potential for rapid, broad, and long-lasting prevention of viral infections as well as immunotherapies in other therapeutic categories. 

Gylden’s T cell-priming vaccines and immunotherapy candidates combine core technologies, [i] a proprietary MHC Class I “Ligandome Library" of experimentally-selected peptide antigens expressed on the surface of pathogen-infected cells, using Immunoproteomics and Multi-Omic technologies, [ii] a proprietary ultrasmall carbohydrate-passivated nanocluster carrier system designed to deliver synthetic peptides to the skin-resident immune system to elicit robust T cell responses, [iii] Microneedle Array Patch (MAP) transdermal delivery technology acquired from Zosano Pharma in 2022, and [iv] in-house GMP accredited nanomedicine manufacturing capabilities.  

Biotechnology

Health Care

Life Sciences

Therapeutics

Gylden Pharma

Thomas Rademacher

This department conducts scientific research and innovation to develop new products and technologies.

Research and Development

This department oversees the strategic direction and governance of the organization through its board members.

Board Governance

This department is responsible for the strategic direction and overall management of the organization.

Executive Leadership

This department manages financial oversight and the operational functions required to support organizational infrastructure.

Finance and Operations

This department focuses on the study and development of immunological processes and treatments.

Immunology Department

This department is responsible for ensuring that products and services meet established quality standards and specifications.

Gylden Pharma

Org chart

Teams

Research and Development

Board Governance

Executive Leadership

Finance and Operations

Immunology Department

Quality Assurance

Offices

Gylden Pharma

Org chart

Teams

Research and Development

Board Governance

Executive Leadership

Finance and Operations

Immunology Department

Quality Assurance

Offices

Related companies